Huaren Pharmaceutical Co Ltd Total Liabilities
Huaren Pharmaceutical Co Ltd total liabilities. Based on the latest financial reports, Huaren Pharmaceutical Co Ltd (300110) has total liabilities worth CN¥1.86 Billion CNY (≈ $272.44 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Huaren Pharmaceutical Co Ltd liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Huaren Pharmaceutical Co Ltd (2007–2025)
Total liabilities of Huaren Pharmaceutical Co Ltd from 2007 to 2025. This chart illustrates how Huaren Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore Huaren Pharmaceutical Co Ltd long-term investment intensity to see how much of total assets are deployed in long-term investments.
Huaren Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Huaren Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Orient Electric Limited
NSE:ORIENTELEC
|
India | Rs9.07 Billion |
|
CapitaLand Malaysia Mall Trust
KLSE:5180
|
Malaysia | RM2.44 Billion |
|
Propert & Buil
TA:PTBL
|
Israel | ILA17.26 Billion |
|
Hudson Pacific Properties Inc
NYSE:HPP
|
USA | $4.31 Billion |
|
TFE Co. Ltd.
KQ:425420
|
Korea | ₩50.42 Billion |
|
Electrosteel Castings Limited
NSE:ELECTCAST
|
India | Rs40.16 Billion |
|
Anhui Xinli Finance Co Ltd
SHG:600318
|
China | CN¥2.37 Billion |
|
Eastern & Oriental Bhd
KLSE:3417
|
Malaysia | RM2.55 Billion |
Liability Composition Analysis (2007–2025)
This chart breaks down Huaren Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 300110 total asset value.
Liquidity & Leverage Metrics
Huaren Pharmaceutical Co Ltd Total Liabilities Ratios Explained
Huaren Pharmaceutical Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.82 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.67 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Huaren Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Huaren Pharmaceutical Co Ltd (2007–2025)
The table below shows the annual total liabilities of Huaren Pharmaceutical Co Ltd from 2007 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.79 Billion ≈ $262.36 Million |
-12.72% |
| 2024-12-31 | CN¥2.05 Billion ≈ $300.59 Million |
-14.40% |
| 2023-12-31 | CN¥2.40 Billion ≈ $351.16 Million |
-6.36% |
| 2022-12-31 | CN¥2.56 Billion ≈ $375.01 Million |
-19.87% |
| 2021-12-31 | CN¥3.20 Billion ≈ $467.98 Million |
+194.48% |
| 2020-12-31 | CN¥1.09 Billion ≈ $158.92 Million |
+135.17% |
| 2019-12-31 | CN¥461.81 Million ≈ $67.58 Million |
-48.52% |
| 2018-12-31 | CN¥897.11 Million ≈ $131.28 Million |
-33.00% |
| 2017-12-31 | CN¥1.34 Billion ≈ $195.92 Million |
+11.67% |
| 2016-12-31 | CN¥1.20 Billion ≈ $175.45 Million |
-8.39% |
| 2015-12-31 | CN¥1.31 Billion ≈ $191.52 Million |
+14.62% |
| 2014-12-31 | CN¥1.14 Billion ≈ $167.09 Million |
+25.82% |
| 2013-12-31 | CN¥907.56 Million ≈ $132.80 Million |
+103.63% |
| 2012-12-31 | CN¥445.69 Million ≈ $65.22 Million |
+699.10% |
| 2011-12-31 | CN¥55.77 Million ≈ $8.16 Million |
+17.18% |
| 2010-12-31 | CN¥47.60 Million ≈ $6.96 Million |
-85.22% |
| 2009-12-31 | CN¥321.98 Million ≈ $47.12 Million |
+12.46% |
| 2008-12-31 | CN¥286.30 Million ≈ $41.90 Million |
+61.29% |
| 2007-12-31 | CN¥177.50 Million ≈ $25.97 Million |
-- |
About Huaren Pharmaceutical Co Ltd
Huaren Pharmaceutical Co., Ltd. produces and sells non-PVC soft bag infusions in China. It offers doxofylline, levofloxacin hydrochloride, compound potassium hydrogen phosphate, and caffeine citrate, sodium chloride, glucose, glucose sodium potassium, chloride, compound sodium chloride, sodium lactate ringer, compound electrolyte, and sterilized water injections. The company also provides therape… Read more